Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Profit After Tax (2018 - 2025)

Cyclerion Therapeutics has reported Profit After Tax over the past 7 years, most recently at -$976000.0 for Q3 2025.

  • For Q3 2025, Profit After Tax fell 34.99% year-over-year to -$976000.0; the TTM value through Sep 2025 reached -$2.2 million, up 58.36%, while the annual FY2024 figure was -$3.1 million, 75.72% up from the prior year.
  • Profit After Tax for Q3 2025 was -$976000.0 at Cyclerion Therapeutics, down from -$324000.0 in the prior quarter.
  • Over five years, Profit After Tax peaked at $530000.0 in Q4 2024 and troughed at -$16.2 million in Q2 2021.
  • A 5-year average of -$5.8 million and a median of -$4.3 million in 2022 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: crashed 86.63% in 2022 and later surged 131.29% in 2024.
  • Year by year, Profit After Tax stood at -$10.8 million in 2021, then skyrocketed by 59.88% to -$4.3 million in 2022, then soared by 60.81% to -$1.7 million in 2023, then skyrocketed by 131.29% to $530000.0 in 2024, then crashed by 284.15% to -$976000.0 in 2025.
  • Business Quant data shows Profit After Tax for CYCN at -$976000.0 in Q3 2025, -$324000.0 in Q2 2025, and -$1.4 million in Q1 2025.